Even as it’s moving into the US tobacco alternatives market, Philip Morris International (PMI) may be setting itself up for a future move into the cannabis industry. The company has reportedly purchased a patent for a genetically modified cannabis plant, and is said to have invested $20m in an Israeli company that makes cannabis inhalers.
Meanwhile, an expert on cannabis and behaviour has told ECigIntelligence that reports of 60 people suffering medical ill-effects from vaping products marketed as containing cannabinoid oil suggested symptoms consistent with them having received “tainted product”.
...
Restricted content. Do you want to read more?
Register
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD as a Novel Food: the future for edibles in Europe
Avoid the risks of online misinformation. This report, from our sister platform CBD-Intel, provides an exclusive in-depth analysis with practical information for your business. All you need to know about CBD and Novel Foods in one place!
Do you want to understand the industry impact of Novel Food regulations and future scenarios? Then you cannot miss our new report.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.
